bio x cell rrid ab 1107769 Search Results


isotype antibody  (Bio X Cell)
98
Bio X Cell isotype antibody
Isotype Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bio+x+cell+rrid+ab+1107769/InVivoMAb+rat+IgG2a+isotype+control%2C+anti-trinitrophenol/pmc12802582-82-8-16
Average 98 stars, based on 1 article reviews
isotype antibody - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier
bp0089 rrid ab 1107769 rat igg1 bio x cell  (Bio X Cell)
96
Bio X Cell bp0089 rrid ab 1107769 rat igg1 bio x cell
Figure 3. CD137 promotes Tex cell expansion and differentiation (A–D) Naive WT mice were treated with anti-CD137 (3H3, 10 mg) or <t>IgG</t> control mAbs. (A) Experimental design. (B–D) FACS plot and graphs showing Ki-67 expression by the indicated CD8+ T cell subsets along treatment.
Bp0089 Rrid Ab 1107769 Rat Igg1 Bio X Cell, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bio+x+cell+rrid+ab+1107769/InVivoPlus+rat+IgG2a+isotype+control%2C+anti-trinitrophenol/pm37392737-231-176-181
Average 96 stars, based on 1 article reviews
bp0089 rrid ab 1107769 rat igg1 bio x cell - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
be0146 rrid ab 10949053 invivoplus rat igg2a isotype control bio x cell cat be0089 rrid ab 1107769 anti suv39h1  (Bio X Cell)
99
Bio X Cell be0146 rrid ab 10949053 invivoplus rat igg2a isotype control bio x cell cat be0089 rrid ab 1107769 anti suv39h1
Figure 3. CD137 promotes Tex cell expansion and differentiation (A–D) Naive WT mice were treated with anti-CD137 (3H3, 10 mg) or <t>IgG</t> control mAbs. (A) Experimental design. (B–D) FACS plot and graphs showing Ki-67 expression by the indicated CD8+ T cell subsets along treatment.
Be0146 Rrid Ab 10949053 Invivoplus Rat Igg2a Isotype Control Bio X Cell Cat Be0089 Rrid Ab 1107769 Anti Suv39h1, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bio+x+cell+rrid+ab+1107769/InVivoMAb+anti-mouse+PD-1/pm37267951-223-224-232
Average 99 stars, based on 1 article reviews
be0146 rrid ab 10949053 invivoplus rat igg2a isotype control bio x cell cat be0089 rrid ab 1107769 anti suv39h1 - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
mouse igg2a isotype control  (Bio X Cell)
95
Bio X Cell mouse igg2a isotype control
Figure 3. CD137 promotes Tex cell expansion and differentiation (A–D) Naive WT mice were treated with anti-CD137 (3H3, 10 mg) or <t>IgG</t> control mAbs. (A) Experimental design. (B–D) FACS plot and graphs showing Ki-67 expression by the indicated CD8+ T cell subsets along treatment.
Mouse Igg2a Isotype Control, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bio+x+cell+rrid+ab+1107769/RecombiMAb+mouse+IgG2a+isotype+control%2C+unknown+specificity/bio_rxiv__2022__04__07__487579-64-9-13
Average 95 stars, based on 1 article reviews
mouse igg2a isotype control - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
rat igg2a  (Bio X Cell)
95
Bio X Cell rat igg2a
Figure 3. CD137 promotes Tex cell expansion and differentiation (A–D) Naive WT mice were treated with anti-CD137 (3H3, 10 mg) or <t>IgG</t> control mAbs. (A) Experimental design. (B–D) FACS plot and graphs showing Ki-67 expression by the indicated CD8+ T cell subsets along treatment.
Rat Igg2a, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bio+x+cell+rrid+ab+1107769/InVivoMAb+anti-rat+IgG2a/pmc10524267-88-20-24
Average 95 stars, based on 1 article reviews
rat igg2a - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
be0075 1 rrid ab 1107721 invivomab rat igg2a isotype control antibody bio x cell bio x cell cat be0089 rrid ab 1107769 bacterial  (Bio X Cell)
96
Bio X Cell be0075 1 rrid ab 1107721 invivomab rat igg2a isotype control antibody bio x cell bio x cell cat be0089 rrid ab 1107769 bacterial
Figure 3. CD137 promotes Tex cell expansion and differentiation (A–D) Naive WT mice were treated with anti-CD137 (3H3, 10 mg) or <t>IgG</t> control mAbs. (A) Experimental design. (B–D) FACS plot and graphs showing Ki-67 expression by the indicated CD8+ T cell subsets along treatment.
Be0075 1 Rrid Ab 1107721 Invivomab Rat Igg2a Isotype Control Antibody Bio X Cell Bio X Cell Cat Be0089 Rrid Ab 1107769 Bacterial, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bio+x+cell+rrid+ab+1107769/InVivoMAb+anti-mouse+Ly6G+Ly6C/pm31665625-151-70-78
Average 96 stars, based on 1 article reviews
be0075 1 rrid ab 1107721 invivomab rat igg2a isotype control antibody bio x cell bio x cell cat be0089 rrid ab 1107769 bacterial - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
isotype control igg  (Bio X Cell)
96
Bio X Cell isotype control igg
Second-generation CPIs synergize with TGFβ blockade to delay tumor growth through CD8+T cells. (A) Female BALB/c mice were injected subcutaneously (s.c.) with 2.5×10 5 syngeneic CT26 tumor cells and treated with <t>isotype-matched</t> <t>control</t> <t>IgG,</t> <t>anti-KLRG1,</t> anti-Tim3, anti-TIGIT or anti-LAG-3 antibodies (all 200 µg/dose) or the combination of those with (B, C) anti-TGFβ (100 µg/dose) starting 8 days post-tumor inoculation. Tumor growth was tracked and grouped analysis (n=10 per group) are shown. (D) Survival analysis of mice injected with CT26 tumor cells on day 0 and treated with the indicated CPIs. (E, F) Mice injected with CT26 were administered antibodies against CD4, CD8, or both starting −1 day before the start of the indicated CPI regimen and T cell depletions were continued twice a week until termination of the study. The data are represented as the mean±SEM and represent two independent experiments. P values are shown for entirety of study using two-way ANOVA test with post hoc Tukey’s multiple comparisons; **p<0.01; ****p<0.0001. Survival differences of tumor-bearing mice were assessed using Kaplan-Meier curves and analyzed by log-rank testing. ANOVA, analysis of variance; CPI, checkpoint inhibitor; PBS, phosphate-buffered saline.
Isotype Control Igg, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bio+x+cell+rrid+ab+1107769/InVivoMAb+Armenian+hamster+IgG+isotype+control%2C+anti-glutathione+S-transferase/pmc11218019-78-29-35
Average 96 stars, based on 1 article reviews
isotype control igg - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
be0089 rrid ab 1107769 invivoplus polyclonal syrian hamster igg bio x cell  (Bio X Cell)
94
Bio X Cell be0089 rrid ab 1107769 invivoplus polyclonal syrian hamster igg bio x cell
Second-generation CPIs synergize with TGFβ blockade to delay tumor growth through CD8+T cells. (A) Female BALB/c mice were injected subcutaneously (s.c.) with 2.5×10 5 syngeneic CT26 tumor cells and treated with <t>isotype-matched</t> <t>control</t> <t>IgG,</t> <t>anti-KLRG1,</t> anti-Tim3, anti-TIGIT or anti-LAG-3 antibodies (all 200 µg/dose) or the combination of those with (B, C) anti-TGFβ (100 µg/dose) starting 8 days post-tumor inoculation. Tumor growth was tracked and grouped analysis (n=10 per group) are shown. (D) Survival analysis of mice injected with CT26 tumor cells on day 0 and treated with the indicated CPIs. (E, F) Mice injected with CT26 were administered antibodies against CD4, CD8, or both starting −1 day before the start of the indicated CPI regimen and T cell depletions were continued twice a week until termination of the study. The data are represented as the mean±SEM and represent two independent experiments. P values are shown for entirety of study using two-way ANOVA test with post hoc Tukey’s multiple comparisons; **p<0.01; ****p<0.0001. Survival differences of tumor-bearing mice were assessed using Kaplan-Meier curves and analyzed by log-rank testing. ANOVA, analysis of variance; CPI, checkpoint inhibitor; PBS, phosphate-buffered saline.
Be0089 Rrid Ab 1107769 Invivoplus Polyclonal Syrian Hamster Igg Bio X Cell, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bio+x+cell+rrid+ab+1107769/InVivoPlus+polyclonal+Syrian+hamster+IgG/pm37625401-632-115-122
Average 94 stars, based on 1 article reviews
be0089 rrid ab 1107769 invivoplus polyclonal syrian hamster igg bio x cell - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
invivomab anti mouse gm csf  (Bio X Cell)
94
Bio X Cell invivomab anti mouse gm csf
Second-generation CPIs synergize with TGFβ blockade to delay tumor growth through CD8+T cells. (A) Female BALB/c mice were injected subcutaneously (s.c.) with 2.5×10 5 syngeneic CT26 tumor cells and treated with <t>isotype-matched</t> <t>control</t> <t>IgG,</t> <t>anti-KLRG1,</t> anti-Tim3, anti-TIGIT or anti-LAG-3 antibodies (all 200 µg/dose) or the combination of those with (B, C) anti-TGFβ (100 µg/dose) starting 8 days post-tumor inoculation. Tumor growth was tracked and grouped analysis (n=10 per group) are shown. (D) Survival analysis of mice injected with CT26 tumor cells on day 0 and treated with the indicated CPIs. (E, F) Mice injected with CT26 were administered antibodies against CD4, CD8, or both starting −1 day before the start of the indicated CPI regimen and T cell depletions were continued twice a week until termination of the study. The data are represented as the mean±SEM and represent two independent experiments. P values are shown for entirety of study using two-way ANOVA test with post hoc Tukey’s multiple comparisons; **p<0.01; ****p<0.0001. Survival differences of tumor-bearing mice were assessed using Kaplan-Meier curves and analyzed by log-rank testing. ANOVA, analysis of variance; CPI, checkpoint inhibitor; PBS, phosphate-buffered saline.
Invivomab Anti Mouse Gm Csf, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bio+x+cell+rrid+ab+1107769/InVivoMAb+anti-mouse+GM-CSF/pm40343794-233-216-221
Average 94 stars, based on 1 article reviews
invivomab anti mouse gm csf - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
pd1, mouse(rmp1-14)  (Biotium)
99
Biotium pd1, mouse(rmp1-14)
Second-generation CPIs synergize with TGFβ blockade to delay tumor growth through CD8+T cells. (A) Female BALB/c mice were injected subcutaneously (s.c.) with 2.5×10 5 syngeneic CT26 tumor cells and treated with <t>isotype-matched</t> <t>control</t> <t>IgG,</t> <t>anti-KLRG1,</t> anti-Tim3, anti-TIGIT or anti-LAG-3 antibodies (all 200 µg/dose) or the combination of those with (B, C) anti-TGFβ (100 µg/dose) starting 8 days post-tumor inoculation. Tumor growth was tracked and grouped analysis (n=10 per group) are shown. (D) Survival analysis of mice injected with CT26 tumor cells on day 0 and treated with the indicated CPIs. (E, F) Mice injected with CT26 were administered antibodies against CD4, CD8, or both starting −1 day before the start of the indicated CPI regimen and T cell depletions were continued twice a week until termination of the study. The data are represented as the mean±SEM and represent two independent experiments. P values are shown for entirety of study using two-way ANOVA test with post hoc Tukey’s multiple comparisons; **p<0.01; ****p<0.0001. Survival differences of tumor-bearing mice were assessed using Kaplan-Meier curves and analyzed by log-rank testing. ANOVA, analysis of variance; CPI, checkpoint inhibitor; PBS, phosphate-buffered saline.
Pd1, Mouse(rmp1 14), supplied by Biotium, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bio+x+cell+rrid+ab+1107769/PD1%2C+Mouse(RMP1-14)/custom%40bnc042002-100%4038227896
Average 99 stars, based on 1 article reviews
pd1, mouse(rmp1-14) - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
anti keyhole limpet hemocyanin  (Bio X Cell)
97
Bio X Cell anti keyhole limpet hemocyanin
Second-generation CPIs synergize with TGFβ blockade to delay tumor growth through CD8+T cells. (A) Female BALB/c mice were injected subcutaneously (s.c.) with 2.5×10 5 syngeneic CT26 tumor cells and treated with <t>isotype-matched</t> <t>control</t> <t>IgG,</t> <t>anti-KLRG1,</t> anti-Tim3, anti-TIGIT or anti-LAG-3 antibodies (all 200 µg/dose) or the combination of those with (B, C) anti-TGFβ (100 µg/dose) starting 8 days post-tumor inoculation. Tumor growth was tracked and grouped analysis (n=10 per group) are shown. (D) Survival analysis of mice injected with CT26 tumor cells on day 0 and treated with the indicated CPIs. (E, F) Mice injected with CT26 were administered antibodies against CD4, CD8, or both starting −1 day before the start of the indicated CPI regimen and T cell depletions were continued twice a week until termination of the study. The data are represented as the mean±SEM and represent two independent experiments. P values are shown for entirety of study using two-way ANOVA test with post hoc Tukey’s multiple comparisons; **p<0.01; ****p<0.0001. Survival differences of tumor-bearing mice were assessed using Kaplan-Meier curves and analyzed by log-rank testing. ANOVA, analysis of variance; CPI, checkpoint inhibitor; PBS, phosphate-buffered saline.
Anti Keyhole Limpet Hemocyanin, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bio+x+cell+rrid+ab+1107769/InVivoMAb+rat+IgG2b+isotype+control%2C+anti-keyhole+limpet+hemocyanin/pm40343794-233-243-248
Average 97 stars, based on 1 article reviews
anti keyhole limpet hemocyanin - by Bioz Stars, 2026-10
97/100 stars
  Buy from Supplier
clone b122  (Bio X Cell)
96
Bio X Cell clone b122
Second-generation CPIs synergize with TGFβ blockade to delay tumor growth through CD8+T cells. (A) Female BALB/c mice were injected subcutaneously (s.c.) with 2.5×10 5 syngeneic CT26 tumor cells and treated with <t>isotype-matched</t> <t>control</t> <t>IgG,</t> <t>anti-KLRG1,</t> anti-Tim3, anti-TIGIT or anti-LAG-3 antibodies (all 200 µg/dose) or the combination of those with (B, C) anti-TGFβ (100 µg/dose) starting 8 days post-tumor inoculation. Tumor growth was tracked and grouped analysis (n=10 per group) are shown. (D) Survival analysis of mice injected with CT26 tumor cells on day 0 and treated with the indicated CPIs. (E, F) Mice injected with CT26 were administered antibodies against CD4, CD8, or both starting −1 day before the start of the indicated CPI regimen and T cell depletions were continued twice a week until termination of the study. The data are represented as the mean±SEM and represent two independent experiments. P values are shown for entirety of study using two-way ANOVA test with post hoc Tukey’s multiple comparisons; **p<0.01; ****p<0.0001. Survival differences of tumor-bearing mice were assessed using Kaplan-Meier curves and analyzed by log-rank testing. ANOVA, analysis of variance; CPI, checkpoint inhibitor; PBS, phosphate-buffered saline.
Clone B122, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bio+x+cell+rrid+ab+1107769/InVivoMAb+anti-mouse+rat+IL-1%CE%B2/pm35908547-262-85-87
Average 96 stars, based on 1 article reviews
clone b122 - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier

Image Search Results


Figure 3. CD137 promotes Tex cell expansion and differentiation (A–D) Naive WT mice were treated with anti-CD137 (3H3, 10 mg) or IgG control mAbs. (A) Experimental design. (B–D) FACS plot and graphs showing Ki-67 expression by the indicated CD8+ T cell subsets along treatment.

Journal: Immunity

Article Title: TCR-independent CD137 (4-1BB) signaling promotes CD8 + -exhausted T cell proliferation and terminal differentiation.

doi: 10.1016/j.immuni.2023.06.007

Figure Lengend Snippet: Figure 3. CD137 promotes Tex cell expansion and differentiation (A–D) Naive WT mice were treated with anti-CD137 (3H3, 10 mg) or IgG control mAbs. (A) Experimental design. (B–D) FACS plot and graphs showing Ki-67 expression by the indicated CD8+ T cell subsets along treatment.

Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Anti-mouse CD45.1- FITC (A20) BD Biosciences Cat#: 110706 RRID: AB_313495 Anti-mouse TCRb-Perc PCy5.5 (H57-597) BioLegend Cat#:109228 RRID: AB_1575173 Anti-mouse CD155 (PVR) PE (TX56) BioLegend Cat#:131508 RRID: AB_1279107 Anti-mouse TIGIT-PeCy7 (1G9) BioLegend Cat#:142108 RRID: AB_2565649 Anti-mouse TIGIT-APC (1G9) BioLegend Cat#: 142105; RRID: AB_10962572 Anti-mouse Eomes-efluor660 (DAN11MAC) Thermo Fisher Scientific Cat#:50-4875-80 RRID: AB_2574227 Anti-mouse Ki67-AF700 (SOLA15) Thermo Fisher Scientific Cat#:56-5698-92 RRID: AB_2637480 Anti-mouse Eomes-EF450 (DAN11MAC) Thermo Fisher Scientific Cat#:48-4875-82 RRID: AB_2574062 Anti-mouse IFNg BV421 (XMG1.2) BD Biosciences Cat#: 505830 RRID: AB_2563105 Anti-mouse CD226-BV421 (TX42.1) BioLegend Cat#:133615 RRID: AB_2715977 Anti-mouse TCRb-BV510 (H57-597) Biolegend Cat#:109233 RRID: AB_2562349 Anti-mouse TCRb-PercPCy5.5 (H57-597) BioLegend Cat#:109228 RRID: AB_1575173 Anti-mouse CD62L-APC (MEL-14) invitrogen Cat#: 17-0621-81 RRID: AB_469410 Anti-mouse PD1 (CD279)-BV785 (29F.1A12) BioLegend Cat#:135225 RRID: AB_2563680 Anti-mouse PD-1 Bio X Cell Cat#: BP0146 RRID: AB_10949053 Anti-mouse OX40 Bio X Cell Cat#: BE0031 RRID: AB_1107592 Anti-mouse 4-1BB (CD137, 3H3) Bio X Cell Cat#: BE0239 RRID: AB_2687721 Anti-mouse 4-1BB (CD137, LOB12.3) Bio X Cell Cat#: BE0239 RRID: AB_10949016 Anti-mouse GITR Bio X Cell Cat#: BE0063 RRID: AB_1107688 Rat IgG2a Bio X Cell Cat#: BP0089 RRID: AB_1107769 Rat IgG1 Bio X Cell Cat#: BP0169 RRID: AB_1107775 Chemicals, peptides, and recombinant proteins Recombinant murine IL-7 Peprotech Cat#: 217-17 Brefeldin A Solution (1000X) Thermo Fisher Scientific Cat#: 00-4506-51 Golgi Plug BD Biosciences Cat#: 555029 Protein Transport Inhibitor BD Biosciences Cat#: 554724 Ionomycin Sigma-Aldrich Cat#: I0634 Phorboll 12-myristate 13-acetate (PMA) Sigma-Aldrich Cat#: P8139 RPMI Medium 1640 Thermo Fisher Scientific Cat#: 61870-010 Fetal Bovine Serum N/A N/A Ficoll Paque Plus Sigma-Aldrich Cat#: 17-1440-03 Acridine Orange / Propidium Iodide (AO/PI) Logos Biosystems Cat#: F23001 (Continued on next page) e2 Immunity 56, 1631–1648.e1–e10, July 11, 2023

Techniques: Control, Expressing

Figure 5. T cell-intrinsic CD137-induced canonical NF-kB signaling drives T cell exhaustion (A–D) Cd4creCd137fl/flROSA26tomato (tomato+) and Cd137fl/flROSA26tomato (tomato) mixed BM chimeras were treated with anti-CD137 (10 mg; 3H3, i.p. twice a week) or IgG control mAbs. (A) Experimental design. (B) Ratio of tomato and tomato+ among splenic CD8+ T cells. (C) Frequency and absolute number of CD8+

Journal: Immunity

Article Title: TCR-independent CD137 (4-1BB) signaling promotes CD8 + -exhausted T cell proliferation and terminal differentiation.

doi: 10.1016/j.immuni.2023.06.007

Figure Lengend Snippet: Figure 5. T cell-intrinsic CD137-induced canonical NF-kB signaling drives T cell exhaustion (A–D) Cd4creCd137fl/flROSA26tomato (tomato+) and Cd137fl/flROSA26tomato (tomato) mixed BM chimeras were treated with anti-CD137 (10 mg; 3H3, i.p. twice a week) or IgG control mAbs. (A) Experimental design. (B) Ratio of tomato and tomato+ among splenic CD8+ T cells. (C) Frequency and absolute number of CD8+

Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Anti-mouse CD45.1- FITC (A20) BD Biosciences Cat#: 110706 RRID: AB_313495 Anti-mouse TCRb-Perc PCy5.5 (H57-597) BioLegend Cat#:109228 RRID: AB_1575173 Anti-mouse CD155 (PVR) PE (TX56) BioLegend Cat#:131508 RRID: AB_1279107 Anti-mouse TIGIT-PeCy7 (1G9) BioLegend Cat#:142108 RRID: AB_2565649 Anti-mouse TIGIT-APC (1G9) BioLegend Cat#: 142105; RRID: AB_10962572 Anti-mouse Eomes-efluor660 (DAN11MAC) Thermo Fisher Scientific Cat#:50-4875-80 RRID: AB_2574227 Anti-mouse Ki67-AF700 (SOLA15) Thermo Fisher Scientific Cat#:56-5698-92 RRID: AB_2637480 Anti-mouse Eomes-EF450 (DAN11MAC) Thermo Fisher Scientific Cat#:48-4875-82 RRID: AB_2574062 Anti-mouse IFNg BV421 (XMG1.2) BD Biosciences Cat#: 505830 RRID: AB_2563105 Anti-mouse CD226-BV421 (TX42.1) BioLegend Cat#:133615 RRID: AB_2715977 Anti-mouse TCRb-BV510 (H57-597) Biolegend Cat#:109233 RRID: AB_2562349 Anti-mouse TCRb-PercPCy5.5 (H57-597) BioLegend Cat#:109228 RRID: AB_1575173 Anti-mouse CD62L-APC (MEL-14) invitrogen Cat#: 17-0621-81 RRID: AB_469410 Anti-mouse PD1 (CD279)-BV785 (29F.1A12) BioLegend Cat#:135225 RRID: AB_2563680 Anti-mouse PD-1 Bio X Cell Cat#: BP0146 RRID: AB_10949053 Anti-mouse OX40 Bio X Cell Cat#: BE0031 RRID: AB_1107592 Anti-mouse 4-1BB (CD137, 3H3) Bio X Cell Cat#: BE0239 RRID: AB_2687721 Anti-mouse 4-1BB (CD137, LOB12.3) Bio X Cell Cat#: BE0239 RRID: AB_10949016 Anti-mouse GITR Bio X Cell Cat#: BE0063 RRID: AB_1107688 Rat IgG2a Bio X Cell Cat#: BP0089 RRID: AB_1107769 Rat IgG1 Bio X Cell Cat#: BP0169 RRID: AB_1107775 Chemicals, peptides, and recombinant proteins Recombinant murine IL-7 Peprotech Cat#: 217-17 Brefeldin A Solution (1000X) Thermo Fisher Scientific Cat#: 00-4506-51 Golgi Plug BD Biosciences Cat#: 555029 Protein Transport Inhibitor BD Biosciences Cat#: 554724 Ionomycin Sigma-Aldrich Cat#: I0634 Phorboll 12-myristate 13-acetate (PMA) Sigma-Aldrich Cat#: P8139 RPMI Medium 1640 Thermo Fisher Scientific Cat#: 61870-010 Fetal Bovine Serum N/A N/A Ficoll Paque Plus Sigma-Aldrich Cat#: 17-1440-03 Acridine Orange / Propidium Iodide (AO/PI) Logos Biosystems Cat#: F23001 (Continued on next page) e2 Immunity 56, 1631–1648.e1–e10, July 11, 2023

Techniques: Control

Second-generation CPIs synergize with TGFβ blockade to delay tumor growth through CD8+T cells. (A) Female BALB/c mice were injected subcutaneously (s.c.) with 2.5×10 5 syngeneic CT26 tumor cells and treated with isotype-matched control IgG, anti-KLRG1, anti-Tim3, anti-TIGIT or anti-LAG-3 antibodies (all 200 µg/dose) or the combination of those with (B, C) anti-TGFβ (100 µg/dose) starting 8 days post-tumor inoculation. Tumor growth was tracked and grouped analysis (n=10 per group) are shown. (D) Survival analysis of mice injected with CT26 tumor cells on day 0 and treated with the indicated CPIs. (E, F) Mice injected with CT26 were administered antibodies against CD4, CD8, or both starting −1 day before the start of the indicated CPI regimen and T cell depletions were continued twice a week until termination of the study. The data are represented as the mean±SEM and represent two independent experiments. P values are shown for entirety of study using two-way ANOVA test with post hoc Tukey’s multiple comparisons; **p<0.01; ****p<0.0001. Survival differences of tumor-bearing mice were assessed using Kaplan-Meier curves and analyzed by log-rank testing. ANOVA, analysis of variance; CPI, checkpoint inhibitor; PBS, phosphate-buffered saline.

Journal: Journal for Immunotherapy of Cancer

Article Title: Second-generation checkpoint inhibitors and Treg depletion synergize with a mouse cancer vaccine in accordance with tumor microenvironment characterization

doi: 10.1136/jitc-2024-008970

Figure Lengend Snippet: Second-generation CPIs synergize with TGFβ blockade to delay tumor growth through CD8+T cells. (A) Female BALB/c mice were injected subcutaneously (s.c.) with 2.5×10 5 syngeneic CT26 tumor cells and treated with isotype-matched control IgG, anti-KLRG1, anti-Tim3, anti-TIGIT or anti-LAG-3 antibodies (all 200 µg/dose) or the combination of those with (B, C) anti-TGFβ (100 µg/dose) starting 8 days post-tumor inoculation. Tumor growth was tracked and grouped analysis (n=10 per group) are shown. (D) Survival analysis of mice injected with CT26 tumor cells on day 0 and treated with the indicated CPIs. (E, F) Mice injected with CT26 were administered antibodies against CD4, CD8, or both starting −1 day before the start of the indicated CPI regimen and T cell depletions were continued twice a week until termination of the study. The data are represented as the mean±SEM and represent two independent experiments. P values are shown for entirety of study using two-way ANOVA test with post hoc Tukey’s multiple comparisons; **p<0.01; ****p<0.0001. Survival differences of tumor-bearing mice were assessed using Kaplan-Meier curves and analyzed by log-rank testing. ANOVA, analysis of variance; CPI, checkpoint inhibitor; PBS, phosphate-buffered saline.

Article Snippet: In vivo depletion of CD4+T cells, CD8+T cells or the combination of the two was achieved by intraperitoneal injection of anti-CD4 (clone GK1.5, RRID:AB_1107636), anti-CD8 (clone 53–6.7, RRID:AB_1107671) or isotype control IgG (RRID:AB_1107769) (all from BioXCell) with a 200 μg dose of antibody −2 days before CPI administration and a 100 μg dose every 2–3 days after that, continuing until termination of the study.

Techniques: Injection, Control, Saline